当前位置: 首页 >> 检索结果
181. Rapidly Improving ARDS in Therapeutic Randomized Controlled Trials.
作者: Edward J Schenck.;Clara Oromendia.;Lisa K Torres.;David A Berlin.;Augustine M K Choi.;Ilias I Siempos.
来源: Chest. 2019年155卷3期474-482页
Observational studies suggest that some patients meeting criteria for ARDS no longer fulfill the oxygenation criterion early in the course of their illness. This subphenotype of rapidly improving ARDS has not been well characterized. We attempted to assess the prevalence, characteristics, and outcomes of rapidly improving ARDS and to identify which variables are useful to predict it.
182. Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial.
作者: Ori Wand.;Elad Guber.;Alexander Guber.;Gali Epstein Shochet.;Lilach Israeli-Shani.;David Shitrit.
来源: Chest. 2018年154卷6期1379-1384页
Tranexamic acid (TA) is an antifibrinolytic drug currently used systemically to control bleeding. To date, there have been no prospective studies of the effectiveness of inhaled TA for the treatment of hemoptysis.
183. Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During Bronchoscopy.
作者: Nicholas J Pastis.;Lonny B Yarmus.;Frank Schippers.;Randall Ostroff.;Alexander Chen.;Jason Akulian.;Momen Wahidi.;Samira Shojaee.;Nichole T Tanner.;Sean P Callahan.;Gregory Feldman.;Daniel G Lorch.;Ikeadi Ndukwu.;Michael A Pritchett.;Gerard A Silvestri.; .
来源: Chest. 2019年155卷1期137-146页
While the complexity of flexible bronchoscopy has increased, standard options for moderate sedation medications have not changed in three decades. There is a need to improve moderate sedation while maintaining safety. Remimazolam was developed to address shortcomings of current sedation strategies.
184. Chest CT Scan at Radiation Dose of a Posteroanterior and Lateral Chest Radiograph Series: A Proof of Principle in Lymphangioleiomyomatosis.
作者: Eileen Hu-Wang.;John L Schuzer.;Shirley Rollison.;Eric S Leifer.;Chloe Steveson.;Vissaagan Gopalakrishnan.;Jianhua Yao.;Tania Machado.;Amanda M Jones.;Patricia Julien-Williams.;Joel Moss.;Marcus Y Chen.
来源: Chest. 2019年155卷3期528-533页
Given the rising utilization of medical imaging and the risks of radiation, there is increased interest in reducing radiation exposure. The objective of this study was to evaluate, as a proof of principle, CT scans performed at radiation doses equivalent to that of a posteroanterior and lateral chest radiograph series in the cystic lung disease lymphangioleiomyomatosis (LAM).
185. The Effects of Long-term CPAP on Weight Change in Patients With Comorbid OSA and Cardiovascular Disease: Data From the SAVE Trial.
作者: Qiong Ou.;Baixin Chen.;Kelly A Loffler.;Yuanming Luo.;Xilong Zhang.;Rui Chen.;Qian Wang.;Luciano F Drager.;Geraldo Lorenzi-Filho.;Michael Hlavac.;Nigel McArdle.;Sutapa Mukherjee.;Olga Mediano.;Ferran Barbe.;Craig S Anderson.;R Doug McEvoy.;Richard J Woodman.; .
来源: Chest. 2019年155卷4期720-729页
Although recent evidence suggests that OSA treatment may cause weight gain, the long-term effects of CPAP on weight are not well established.
186. Impact of Vasoactive Medications on ICU-Acquired Weakness in Mechanically Ventilated Patients.
作者: Krysta S Wolfe.;Bhakti K Patel.;Erica L MacKenzie.;Shewit P Giovanni.;Anne S Pohlman.;Matthew M Churpek.;Jesse B Hall.;John P Kress.
来源: Chest. 2018年154卷4期781-787页
Vasoactive medications are commonly used in the treatment of critically ill patients, but their impact on the development of ICU-acquired weakness is not well described. The objective of this study is to evaluate the relationship between vasoactive medication use and the outcome of ICU-acquired weakness.
187. Effects of Exercise Training and CPAP in Patients With Heart Failure and OSA: A Preliminary Study.
作者: Denise Maria Servantes.;Shahrokh Javaheri.;Ana Claudia Pelissari Kravchychyn.;Luciana Julio Storti.;Dirceu Rodrigues Almeida.;Marco Túlio de Mello.;Fátima Dumas Cintra.;Sergio Tufik.;Lia Bittencourt.
来源: Chest. 2018年154卷4期808-817页
Exercise and CPAP improve OSA. This study examined the effects of exercise in patients with heart failure (HF) and OSA.
188. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
作者: Scott M Palmer.;Laurie Snyder.;Jamie L Todd.;Benjamin Soule.;Rose Christian.;Kevin Anstrom.;Yi Luo.;Robert Gagnon.;Glenn Rosen.
来源: Chest. 2018年154卷5期1061-1069页
Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function. The lysophosphatidic acid receptor 1 (LPA1) pathway is implicated in IPF etiology. Safety and efficacy of BMS-986020, a high-affinity LPA1 antagonist, was assessed vs placebo in a phase 2 study in patients with IPF.
189. Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.
作者: Anthony M Lamattina.;Angelo Taveira-Dasilva.;Hilary J Goldberg.;Shefali Bagwe.;Ye Cui.;Ivan O Rosas.;Joel Moss.;Elizabeth P Henske.;Souheil El-Chemaly.
来源: Chest. 2018年154卷5期1070-1082页
We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM). The goal of the present study was to analyze sera from the SAIL trial to identify novel biomarkers that could shed light into disease pathogenesis and response to therapy.
190. Standard Bronchoscopy With Fluoroscopy vs Thin Bronchoscopy and Radial Endobronchial Ultrasound for Biopsy of Pulmonary Lesions: A Multicenter, Prospective, Randomized Trial.
作者: Nichole T Tanner.;Lonny Yarmus.;Alexander Chen.;Jessica Wang Memoli.;Hiren J Mehta.;Nicholas J Pastis.;Hans Lee.;Michael A Jantz.;Paul J Nietert.;Gerard A Silvestri.
来源: Chest. 2018年154卷5期1035-1043页
New technology has resulted in bronchoscopy being increasingly used for diagnosing pulmonary lesions. Reported yield from these procedures varies widely with few randomized clinical trials. This study compares the diagnostic yield of a thin bronchoscope and radial endobronchial ultrasound (R-EBUS) with standard bronchoscopy and fluoroscopy (SB-F) in lung lesions.
191. Surgical Disparities Among Patients With Stage I Lung Cancer in the National Lung Screening Trial.
Low-dose CT scan reduces lung cancer mortality in high-risk patients fit to undergo surgical resection. Racial disparities in resection of lung cancer in nonscreening populations are well described. We describe surgical resection patterns of patients with early stage non-small cell lung cancer (NSCLC) in the National Lung Screening Trial (NLST) and examine whether racial disparities exist among blacks.
192. Efficacy of Dexamethasone in Preventing Acute Mountain Sickness in COPD Patients: Randomized Trial.
作者: Michael Furian.;Mona Lichtblau.;Sayaka S Aeschbacher.;Bermet Estebesova.;Berik Emilov.;Ulan Sheraliev.;Nuriddin H Marazhapov.;Maamed Mademilov.;Batyr Osmonov.;Maya Bisang.;Stefanie Ulrich.;Tsogyal D Latshang.;Silvia Ulrich.;Talant M Sooronbaev.;Konrad E Bloch.
来源: Chest. 2018年154卷4期788-797页
Patients with COPD may experience acute mountain sickness (AMS) and other altitude-related adverse health effects (ARAHE) when traveling to high altitudes. This study evaluated whether dexamethasone, a drug used for the prevention of AMS in healthy individuals, would prevent AMS/ARAHE in patients with COPD.
193. Can Patients With COPD Assimilate Disease-Specific Information During an Acute Exacerbation?: Results of a Pilot Randomized Controlled Trial.
作者: Tania Janaudis-Ferreira.;Sylvia Jocelyn Carr.;Samantha L Harrison.;Andrea S Gershon.;Siobhan C Milner.;Sean Carr.;David Fishbein.;Roger Goldstein.
来源: Chest. 2018年154卷3期588-596页
The study aimed to determine the feasibility and effectiveness of an introductory disease-specific educational program delivered during an acute exacerbation of COPD (AECOPD) on objective measures of disease-specific knowledge.
194. Left Atrial Volume as a Biomarker of Target Organ Damage in Cardionephrology: A Study in a Wide Range of Renal Function.
作者: Zach Rozenbaum.;Orit Kliuk Ben-Bassat.;Yitzhak Hadad.;Moshe Iluz.;Yoav Granot.;Tomer Ziv-Baran.;Shlomo Berliner.;Galit Aviram.
来源: Chest. 2018年154卷4期893-903页
Cardiac chamber size was previously studied by echocardiography, among patients with progressive kidney disease only. We aimed to explore the relations between all heart chamber volumes as assessed by CT pulmonary angiography and renal function, throughout all ranges.
195. Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial.
作者: Alana M Rojewski.;Nichole T Tanner.;Lin Dai.;James G Ravenel.;Mulugeta Gebregziabher.;Gerard A Silvestri.;Benjamin A Toll.
来源: Chest. 2018年154卷1期110-118页
Incorporating tobacco treatment within lung cancer screening programs has the potential to influence cessation in high-risk smokers. We aimed to better understand the characteristics of smokers within a screening cohort, correlate those variables with downstream outcomes, and identify predictors of continued smoking.
196. Persistence of Central Venous Oxygen Desaturation During Early Sepsis Is Associated With Higher Mortality: A Retrospective Analysis of the ALBIOS Trial.
作者: Alessandro Protti.;Serge Masson.;Roberto Latini.;Roberto Fumagalli.;Marilena Romero.;Carla Pessina.;Giovanni Pasetti.;Gianni Tognoni.;Antonio Pesenti.;Luciano Gattinoni.;Pietro Caironi.
来源: Chest. 2018年154卷6期1291-1300页
Relevance of low (< 70%) central venous oxygen saturation (Scvo2) during early sepsis has been recently questioned by three negative trials (Protocol-Based Care for Early Septic Shock, Australasian Resuscitation in Sepsis Evaluation, and Protocolized Management in Sepsis) on early goal-directed therapy; however, subjects included in those trials had Scvo2 at enrollment as high as 71 ± 13%, 73 ± 11%, and 70 ± 12%. Here we assess the association between Scvo2 < 70% at 6 h and 90-day mortality in subjects enrolled in the Albumin Italian Outcome Sepsis (ALBIOS) trial, focusing on those with initial Scvo2 < 70%.
197. Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial.
作者: Kelly M Chin.;Mardi Gomberg-Maitland.;Richard N Channick.;Michael J Cuttica.;Aryeh Fischer.;Robert P Frantz.;Elke Hunsche.;Leah Kleinman.;John W McConnell.;Vallerie V McLaughlin.;Chad E Miller.;Roham T Zamanian.;Michael S Zastrow.;David B Badesch.
来源: Chest. 2018年154卷4期848-861页
Disease-specific patient-reported outcome (PRO) instruments are important in assessing the impact of disease and treatment. The Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire is the first instrument for quantifying pulmonary arterial hypertension (PAH) symptoms and impacts developed according to the 2009 US Food and Drug Administration PRO guidance; previous qualitative research in patients with PAH supported its initial content validity.
198. Acute Tetrahydrobiopterin Improves Endothelial Function in Patients With COPD.
作者: Paula Rodriguez-Miguelez.;Justin Gregg.;Nichole Seigler.;Leon Bass.;Jeffrey Thomas.;Jennifer S Pollock.;Jennifer C Sullivan.;Thomas A Dillard.;Ryan A Harris.
来源: Chest. 2018年154卷3期597-606页
Cardiovascular diseases represent a hallmark characteristic in COPD, and endothelial dysfunction has been observed in these patients. Tetrahydrobiopterin (BH4) is an essential cofactor for nitric oxide (NO) synthesis and a regulator of endothelial function. The goal of this study was to test the hypothesis that a single dose of BH4 would improve endothelial function in patients with COPD via an increase in NO bioavailability.
199. Comparison of Two Lidocaine Administration Techniques on Perceived Pain From Bedside Procedures: A Randomized Clinical Trial.
作者: Bhakti K Patel.;Blair N Wendlandt.;Krysta S Wolfe.;Shruti B Patel.;Elizabeth R Doman.;Anne S Pohlman.;Jesse B Hall.;John P Kress.
来源: Chest. 2018年154卷4期773-780页
Lidocaine is used to alleviate procedural pain but paradoxically increases pain during injection. Pain perception can be modulated by non-noxious stimuli such as temperature or touch according to the gate control theory of pain. We postulated that lidocaine dripped onto the skin prior to injection would cool or add the sensation of touch at the skin surface to reduce pain perception from the procedure.
200. CPAP Adherence Predictors in a Randomized Trial of Moderate-to-Severe OSA Enriched With Women and Minorities.
作者: Anna M May.;Tarek Gharibeh.;Lu Wang.;Amanda Hurley.;Harneet Walia.;Kingman P Strohl.;Reena Mehra.
来源: Chest. 2018年154卷3期567-578页
Suboptimal CPAP adherence in OSA clinical trials involving predominantly white men limits interpretability and generalizability. We examined predictors of CPAP adherence in a clinical trial enriched with minorities.
|